Ontology highlight
ABSTRACT:
SUBMITTER: Ishibashi M
PROVIDER: S-EPMC6205184 | biostudies-literature | 2018 Oct
REPOSITORIES: biostudies-literature
Ishibashi Mariko M Soeda Saori S Sasaki Makoto M Handa Hiroshi H Imai Yoichi Y Tanaka Norina N Tanosaki Sakae S Ito Shigeki S Odajima Takeshi T Sugimori Hiroki H Asayama Toshio T Sunakawa Mika M Kaito Yuta Y Kinoshita Ryosuke R Kuribayashi Yasuko Y Onodera Asaka A Moriya Keiichi K Tanaka Junji J Tsukune Yutaka Y Komatsu Norio N Inokuchi Koiti K Tamura Hideto H
Oncotarget 20181005 78
The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) as well as natural killer (NK) cells and is a well-known therapeutic target of elotuzumab. The objective of this study was to evaluate the clinical significance of serum soluble SLAMF7 (sSLAMF7) levels in patients with MM (n=103) and furthermore the impact of sSLMF7 on the antitumor activity of anti-SLAMF7 antibody. Thirty-one percent of MM pati ...[more]